Literature DB >> 20491784

Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.

F O Pettersen1, K Taskén, D Kvale.   

Abstract

Additional progression markers for human immunodeficiency virus (HIV) infection are warranted. In this study we related antigen-specific responses in CD4(+) and CD8(+) T cells to CD38, reflecting chronic immune activation, and to CD4(+) T cell loss rates. Clones transiently expressing CD107a (CD8(+)) or CD154 (CD4(+)) in response to Gag, Env and Nef overlapping peptide pools were identified, along with their expression of the inhibitory programmed death-1 receptor (PD-1) in fresh peripheral blood mononuclear cells (PBMC) from 31 patients off antiretroviral treatment (ART). HIV-specific CD8(+) T cell responses dominated over CD4(+) T cell responses, and among CD8(+) responses, Gag and Nef responses were higher than Env-responses (P < 0.01). PD-1 on CD8(+) HIV-specific subsets was higher than CMV-specific CD8(+) cells (P < 0.01), whereas PD-1 on HIV-specific CD4(+) cells was similar to PD-1 on CMV-specific CD4(+) cells. Gag and Env CD8(+) responses correlated oppositely to the CD4 loss rate. Env/Gag CD8(+) response ratios, independently of PD-1 levels, correlated more strongly to CD4 change rates (r = -0.50 to -0.77, P < 0.01) than the total number of Gag-specific CD8(+) cells (r = 0.44-0.85, P < or = 0.02). The Env/Gag ratio performed better than CD38 and HIV-RNA in logistic regression analysis predicting CD4 change rate as a measure of progression. In conclusion, HIV-specific CD8(+)CD107a(+) Env/Gag response ratio was a stronger predictor for progression than CD38 and HIV-RNA. The Env/Gag ratio may reflect the balance between possibly beneficial (Gag) and detrimental (Env) CD8(+) T cell responses and should be explored further as a progression marker.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491784      PMCID: PMC2909414          DOI: 10.1111/j.1365-2249.2010.04179.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS.

Authors:  D Kvale; P Aukrust; K Osnes; F Müller; S S Frøland
Journal:  AIDS       Date:  1999-02-04       Impact factor: 4.177

2.  Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia.

Authors:  Dag Kvale; Anne-Marte Bakken Kran; Maja A Sommerfelt; Jørgen Nyhus; Ingebjørg Baksaas; Johan N Bruun; Birger Sørensen
Journal:  AIDS       Date:  2005-03-24       Impact factor: 4.177

3.  Direct access to CD4+ T cells specific for defined antigens according to CD154 expression.

Authors:  Marco Frentsch; Olga Arbach; Dennis Kirchhoff; Beate Moewes; Margitta Worm; Martin Rothe; Alexander Scheffold; Andreas Thiel
Journal:  Nat Med       Date:  2005-09-25       Impact factor: 53.440

Review 4.  The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. UK Register of HIV Seroconverters Steering Committee.

Authors: 
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

5.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Authors:  Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2006-08-20       Impact factor: 53.440

Review 6.  The immunopathogenesis of human immunodeficiency virus infection.

Authors:  G Pantaleo; C Graziosi; A S Fauci
Journal:  N Engl J Med       Date:  1993-02-04       Impact factor: 91.245

7.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

8.  HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).

Authors:  Anne-Marte B Kran; Birger Sørensen; Jørgen Nyhus; Maja A Sommerfelt; Ingebjørg Baksaas; Johan N Bruun; Dag Kvale
Journal:  AIDS       Date:  2004-09-24       Impact factor: 4.177

9.  Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.

Authors:  G Rosignoli; C H Lim; M Bower; F Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.

Authors:  Photini Kiepiela; Kholiswa Ngumbela; Christina Thobakgale; Dhanwanthie Ramduth; Isobella Honeyborne; Eshia Moodley; Shabashini Reddy; Chantal de Pierres; Zenele Mncube; Nompumelelo Mkhwanazi; Karen Bishop; Mary van der Stok; Kriebashnie Nair; Nasreen Khan; Hayley Crawford; Rebecca Payne; Alasdair Leslie; Julia Prado; Andrew Prendergast; John Frater; Noel McCarthy; Christian Brander; Gerald H Learn; David Nickle; Christine Rousseau; Hoosen Coovadia; James I Mullins; David Heckerman; Bruce D Walker; Philip Goulder
Journal:  Nat Med       Date:  2006-12-17       Impact factor: 53.440

View more
  7 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Authors:  Rafael Ribeiro Almeida; Daniela Santoro Rosa; Susan Pereira Ribeiro; Vinicius Canato Santana; Esper Georges Kallás; John Sidney; Alessandro Sette; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

4.  A parameter for IL-10 and TGF-ß mediated regulation of HIV-1 specific T cell activation provides novel information and relates to progression markers.

Authors:  Andreas Lind; Kristin Brekke; Frank Olav Pettersen; Tom Eirik Mollnes; Marius Trøseid; Dag Kvale
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

5.  Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays.

Authors:  Suneth S Perera; Bin Wang; Arturo Damian; Wayne Dyer; Li Zhou; Viviane Conceicao; Nitin K Saksena
Journal:  Microarrays (Basel)       Date:  2016-06-02

6.  Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy.

Authors:  Nicole E Behrens; Anne Wertheimer; Maria B Love; Stephen A Klotz; Nafees Ahmad
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

7.  Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant.

Authors:  Karen S Korsholm; Ingrid Karlsson; Sheila T Tang; Lea Brandt; Else Marie Agger; Claus Aagaard; Peter Andersen; Anders Fomsgaard
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.